Alkermes PLC (ALKS) vs. Its Competitors Critical Comparison

Alkermes PLC (NASDAQ: ALKS) is one of 197 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Alkermes PLC to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.

Risk & Volatility

Alkermes PLC has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Comparatively, Alkermes PLC’s peers have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Alkermes PLC and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes PLC 0 3 4 0 2.57
Alkermes PLC Competitors 471 2236 6133 118 2.66

Alkermes PLC presently has a consensus price target of $65.14, suggesting a potential upside of 29.53%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.93%. Given Alkermes PLC’s higher possible upside, equities research analysts clearly believe Alkermes PLC is more favorable than its peers.

Insider and Institutional Ownership

99.1% of Alkermes PLC shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 5.3% of Alkermes PLC shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Alkermes PLC and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alkermes PLC -24.33% -9.12% -6.40%
Alkermes PLC Competitors -3,989.16% -119.16% -44.12%

Valuation and Earnings

This table compares Alkermes PLC and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Alkermes PLC $804.37 million -$103.30 million -39.29
Alkermes PLC Competitors $207.78 million -$2.31 million 0.49

Alkermes PLC has higher revenue, but lower earnings than its peers. Alkermes PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Alkermes PLC beats its peers on 7 of the 12 factors compared.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply